MARKSANS

Marksans Pharma Shareholding Pattern

₹325.20+0.25%
Market cap
₹14,737 crore
P/E
28.5
P/B
4.87
ROE
15.2%
Dividend yield
0.28%

As of 30-JUN-2026, promoters held 43.87% of Marksans Pharma (0.00 pp from 31-MAR-2026), foreign institutional investors 17.47%, domestic institutions 6.19% and the public 32.47%.

Marksans Pharma shareholding pattern

Percentage of shares held, by quarter, newest first.

Marksans Pharma shareholding by category (% of equity)
Holder30-JUN-202631-MAR-202631-DEC-202530-SEP-202530-JUN-202531-MAR-2025Change
Promoters43.87%43.87%43.87%43.87%43.87%n/a0.00 pp
Foreign institutions (FII/FPI)17.47%16.76%16.74%16.92%19.88%n/a+0.71 pp
Domestic institutions (DII)6.19%6.57%5.91%5.28%5.50%n/a-0.38 pp
Public32.47%32.79%33.47%33.93%30.75%n/a-0.32 pp

Source: Shareholding patterns filed with the stock exchanges (company filings). Data as of 7 October 2026. How this data is compiled.

Marksans Pharma shareholding pattern — frequently asked questions

What is the promoter holding in Marksans Pharma?

Promoters held 43.87% of Marksans Pharma as of 30-JUN-2026, unchanged from 43.87% in 31-MAR-2026.

How much do FIIs hold in Marksans Pharma?

Foreign institutional investors held 17.47% of Marksans Pharma as of 30-JUN-2026, a change of +0.71 pp from the previous quarter.

How much do domestic institutions hold in Marksans Pharma?

Domestic institutional investors, including mutual funds and insurers, held 6.19% of Marksans Pharma as of 30-JUN-2026 (-0.38 pp from the previous quarter).

Who owns Marksans Pharma?

As of 30-JUN-2026, Marksans Pharma's shareholders were promoters (43.87%), foreign institutional investors 17.47%, domestic institutions 6.19% and the public 32.47%, as filed with the stock exchanges.

Same Data For Peers

💡 LearnHow to read a shareholding pattern →

Trade Marksans Pharma With ATS

Track MARKSANS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Marksans Pharma share priceOpen a demat account →Brokerage calculator

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.